Industry
Biotechnology
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
Loading...
Open
1.06
Mkt cap
9.1M
Volume
426K
High
1.06
P/E Ratio
0.21
52-wk high
30.84
Low
0.97
Div yield
N/A
52-wk low
0.95
Portfolio Pulse from Avi Kapoor
March 01, 2024 | 6:19 pm
Portfolio Pulse from Henry Khederian
March 01, 2024 | 3:56 pm
Portfolio Pulse from Benzinga Newsdesk
February 15, 2024 | 1:37 pm
Portfolio Pulse from Avi Kapoor
January 26, 2024 | 12:58 pm
Portfolio Pulse from Avi Kapoor
January 23, 2024 | 12:55 pm
Portfolio Pulse from Benzinga Insights
January 12, 2024 | 1:06 pm
Portfolio Pulse from Benzinga Newsdesk
January 04, 2024 | 1:39 pm
Portfolio Pulse from Bill Haddad
December 29, 2023 | 4:21 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.